ADM Tronics Reports First Quarter of Fiscal Year 2025 Results
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reports positive financial results for the first quarter of Fiscal Year 2025 ended June 30, 2024. Key highlights include:
- Revenue increased by 12% to $857,845 compared to $762,689 in the same period last year
- Net profit of $272,168, a significant improvement from a net loss of $132,261 in the previous year
- Profit from operations of $164,281, compared to a loss of $137,796 in the same quarter last year
- Gross profit increased to $520,903 from $325,142
ADMT completed R&D for its Vet-Sonotron庐 device and is advancing the human medical version. The company plans to pursue FDA 510(k) submission for the human Sonotron庐, targeting non-drug pain treatment.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) riporta risultati finanziari positivi per il primo trimestre dell'anno fiscale 2025, conclusosi il 30 giugno 2024. I punti salienti includono:
- Ricavi aumentati del 12% a $857,845, rispetto a $762,689 nello stesso periodo dell'anno scorso
- Utili netti di $272,168, un miglioramento significativo rispetto a una perdita netta di $132,261 nell'anno precedente
- Profitto operativo di $164,281, rispetto a una perdita di $137,796 nello stesso trimestre dell'anno scorso
- Il profitto lordo 猫 aumentato a $520,903 da $325,142
ADMT ha completato la R&S per il suo dispositivo Vet-Sonotron庐 e sta sviluppando la versione umana. L'azienda prevede di presentare la domanda FDA 510(k) per il Sonotron庐 umano, mirando a un trattamento del dolore non farmacologico.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) informa sobre resultados financieros positivos para el primer trimestre del a帽o fiscal 2025 que finaliz贸 el 30 de junio de 2024. Los aspectos destacados incluyen:
- Los ingresos aumentaron un 12% a $857,845 en comparaci贸n con $762,689 en el mismo per铆odo del a帽o pasado
- Beneficio neto de $272,168, una mejora significativa respecto a una p茅rdida neta de $132,261 del a帽o anterior
- Beneficio operativo de $164,281, en comparaci贸n con una p茅rdida de $137,796 en el mismo trimestre del a帽o pasado
- El beneficio bruto aument贸 a $520,903 desde $325,142
ADMT ha completado la I+D para su dispositivo Vet-Sonotron庐 y est谩 avanzando en la versi贸n m茅dica humana. La compa帽铆a planea presentar la solicitud FDA 510(k) para el Sonotron庐 humano, buscando un tratamiento del dolor no farmacol贸gico.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT)電� 2025 須岅硠鞐半弰 觳� 攵勱赴(2024雲� 6鞗� 30鞚� 毵堦皭)鞐� 雽�頃� 旮嶌爼鞝侅澑 鞛 瓴瓣臣毳� 氤搓碃頄堨姷雼堧嫟. 欤检殧 頃橃澊霛检澊韸鸽姅 雼れ潓瓿� 臧欖姷雼堧嫟:
- 靾橃澋鞚� 12% 歃濌皜頃橃棳 $857,845搿�, 歆�雮滍暣 臧欖潃 旮瓣皠鞚� $762,689鞕� 牍勱祼霅╇媹雼�.
- 靾滌澊鞚奠潃 $272,168鞙茧, 歆�雮滍暣鞚� 靾滌啇鞁� $132,261鞐愳劀 韥矊 臧滌劆霅橃棃鞀惦媹雼�.
- 鞓侅梾鞚挫澋鞚� $164,281鞙茧, 歆�雮滍暣 臧欖潃 攵勱赴鞐愳劀鞚� 靻愳嫟 $137,796瓿� 牍勱祼霅╇媹雼�.
- 齑濎澊鞚奠潃 $520,903鞐愳劀 $325,142搿� 歃濌皜頄堨姷雼堧嫟.
ADMT電� Vet-Sonotron庐 鞛レ箻鞚� 鞐瓣惮臧滊皽鞚� 鞕勲頄堨溂氅�, 鞚戈皠 鞚橅暀 氩勳爠鞙茧 雮橃晞臧�瓿� 鞛堨姷雼堧嫟. 須岇偓電� 牍勳暯氍� 韱奠 旃橂毳� 氇╉憸搿� 頃橂姅 鞚戈皠 Sonotron庐鞐� 雽�頃� FDA 510(k) 鞝滌稖鞚� 於旍頃� 瓿勴殟鞛呺媹雼�.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) rapporte des r茅sultats financiers positifs pour le premier trimestre de l'exercice fiscal 2025, qui s'est termin茅 le 30 juin 2024. Les principaux points forts incluent :
- Les revenus ont augment茅 de 12% pour atteindre 857 845 $, contre 762 689 $ au cours de la m锚me p茅riode l'an dernier
- B茅n茅fice net de 272 168 $, une am茅lioration significative par rapport 脿 une perte nette de 132 261 $ l'ann茅e pr茅c茅dente
- B茅n茅fice d'exploitation de 164 281 $, compar茅 脿 une perte de 137 796 $ au m锚me trimestre l'ann茅e pr茅c茅dente
- Le b茅n茅fice brut a augment茅 脿 520 903 $ contre 325 142 $
ADMT a termin茅 la R&D de son appareil Vet-Sonotron庐 et fait avancer la version m茅dicale humaine. La soci茅t茅 pr茅voit de faire une demande de soumission FDA 510(k) pour le Sonotron庐 humain, visant un traitement de la douleur sans m茅dicaments.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) berichtet 眉ber positive Finanzresultate f眉r das erste Quartal des Gesch盲ftsjahres 2025, das am 30. Juni 2024 endete. Wichtige Highlights sind:
- Umsatz steigerte sich um 12% auf $857,845 im Vergleich zu $762,689 im gleichen Zeitraum des Vorjahres
- Nettoergebnis von $272,168, eine deutliche Verbesserung gegen眉ber einem Nettverlust von $132,261 im Vorjahr
- Betriebsgewinn von $164,281, im Vergleich zu einem Verlust von $137,796 im gleichen Quartal des Vorjahres
- Bruttoertrag erh枚hte sich auf $520,903 von $325,142
ADMT hat die Forschung und Entwicklung f眉r sein Vet-Sonotron庐-Ger盲t abgeschlossen und treibt die menschliche medizinische Version voran. Das Unternehmen plant, einen Antrag auf FDA 510(k) f眉r das menschliche Sonotron庐 einzureichen, um eine nicht-medikament枚se Schmerzbehandlung anzustreben.
- Revenue increased by 12% year-over-year to $857,845
- Net profit of $272,168 compared to a net loss of $132,261 in the previous year
- Profit from operations of $164,281, a 119% increase from the previous year's loss
- Gross profit increased to $520,903 from $325,142
- Completed R&D for Vet-Sonotron庐 device and advancing human medical version
- R&D expenses remained relatively unchanged at $127,993
NORTHVALE, NJ / ACCESSWIRE / August 19, 2024 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2024 of Fiscal Year 2025.
ADMT achieved a profit for the first quarter of Fiscal Year 2025, as compared to loss for the same period last year. Revenues increased over
ADMT completed R&D and engineering efforts of its' Vet-Sonotron ® non-invasive pain treatment device for the veterinary market during the last quarter of fiscal year ended March 31, 2024. () The Company then directed additional R&D and engineering activities to advance the development of the human medical version of this innovative therapeutic technology. As a result, R&D expense for the quarter ended June 30, 2024 was comparable to the same period last year. The Company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Sonotron ® is being developed for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet.
Revenues for the quarter ended June 30, 2024, were
Financial Highlights
| Three Months Ended |
| Three Months Ended |
| ||
| June 30, 2024 |
| June 30, 2023 |
| ||
Net Revenues | $ | 857,845 |
| $ | 762,689 |
|
|
|
|
|
|
|
|
Cost of sales |
| 336,942 |
|
| 437,547 |
|
|
|
|
|
|
|
|
Gross Profit |
| 520,903 |
|
| 325,142 |
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
Research and development |
| 127,993 |
|
| 130,587 |
|
Selling, general and administrative |
| 228,629 |
|
| 332,351 |
|
Total operating expenses |
| 356,622 |
|
| 462,938 |
|
|
|
|
|
|
|
|
Profit (loss) from operations |
| 164,281 |
|
| (137,796 | ) |
|
|
|
|
|
|
|
Total other income |
| 108,387 |
|
| 5,535 |
|
|
|
|
|
|
|
|
Profit (loss) before provision for income taxes |
| 272,668 |
|
| (132,261 | ) |
|
|
|
|
|
|
|
Total benefit (provision) for income taxes |
| 500 |
|
| - |
|
|
|
|
|
|
|
|
Net profit (loss) | $ | 272,168 |
| $ | (132,261 | ) |
|
|
|
|
|
|
|
Basic and diluted earnings (loss) per common share | $ | 0.00 |
| $ | (0.00 | ) |
Weighted average shares of common stock outstanding - basic and diluted |
| 67,588,492 |
|
| 67,588,492 |
|
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at .
To receive ADMT email updates, complete form at
Sonotron ® is a registered trademark of ADM Tronics Unlimited, Inc.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
For more information - Investor Relations:
Howard Isaacs 562-987-4939 [email protected]
Richard Cavalli 303-956-1777 [email protected]
SOURCE: ADM Tronics Unlimited Inc.
View the original on accesswire.com
FAQ
What was ADMT's revenue for Q1 FY2025?
How much profit did ADMT report for Q1 FY2025?
What is the status of ADMT's Vet-Sonotron device development?
Is ADMT planning to seek FDA approval for its Sonotron device?
